TY - JOUR
T1 - Fibre-rich Foods to Treat Obesity and Prevent Colon Cancer trial study protocol
T2 - a randomised clinical trial of fibre-rich legumes targeting the gut microbiome, metabolome and gut transit time of overweight and obese patients with a history of noncancerous adenomatous polyps
AU - Hartman, Terryl J.
AU - Christie, Jennifer
AU - Wilson, Annette
AU - Ziegler, Thomas R.
AU - Methe, Barbara
AU - Flanders, William Dana
AU - Rolls, Barbara J.
AU - Eberhart, Blaine Loye
AU - Li, Jia V.
AU - Huneault, Helaina
AU - Cousineau, Ben
AU - Perez, Miriam R.
AU - O'Keefe, Stephen J.D.
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2024.
PY - 2024/2/5
Y1 - 2024/2/5
N2 - Introduction Recently published studies support the beneficial effects of consuming fibre-rich legumes, such as cooked dry beans, to improve metabolic health and reduce cancer risk. In participants with overweight/obesity and a history of colorectal polyps, the Fibre-rich Foods to Treat Obesity and Prevent Colon Cancer randomised clinical trial will test whether a high-fibre diet featuring legumes will simultaneously facilitate weight reduction and suppress colonic mucosal biomarkers of colorectal cancer (CRC). Methods/design This study is designed to characterise changes in (1) body weight; (2) biomarkers of insulin resistance and systemic inflammation; (3) compositional and functional profiles of the faecal microbiome and metabolome; (4) mucosal biomarkers of CRC risk and (5) gut transit. Approximately 60 overweight or obese adults with a history of noncancerous adenomatous polyps within the previous 3 years will be recruited and randomised to one of two weight-loss diets. Following a 1-week run-in, participants in the intervention arm will receive preportioned high-fibre legume-rich entrées for two meals/ day in months 1–3 and one meal/day in months 4–6. In the control arm, entrées will replace legumes with lean protein sources (eg, chicken). Both groups will receive in-person and written guidance to include nutritionally balanced sides with energy intake to lose 1–2 pounds per week. Ethics and dissemination The National Institutes of Health fund this ongoing 5-year study through a National Cancer Institute grant (5R01CA245063) awarded to Emory University with a subaward to the University of Pittsburgh. The study protocol was approved by the Emory Institutional Review Board (IRB approval number: 00000563). Trial registration number NCT04780477.
AB - Introduction Recently published studies support the beneficial effects of consuming fibre-rich legumes, such as cooked dry beans, to improve metabolic health and reduce cancer risk. In participants with overweight/obesity and a history of colorectal polyps, the Fibre-rich Foods to Treat Obesity and Prevent Colon Cancer randomised clinical trial will test whether a high-fibre diet featuring legumes will simultaneously facilitate weight reduction and suppress colonic mucosal biomarkers of colorectal cancer (CRC). Methods/design This study is designed to characterise changes in (1) body weight; (2) biomarkers of insulin resistance and systemic inflammation; (3) compositional and functional profiles of the faecal microbiome and metabolome; (4) mucosal biomarkers of CRC risk and (5) gut transit. Approximately 60 overweight or obese adults with a history of noncancerous adenomatous polyps within the previous 3 years will be recruited and randomised to one of two weight-loss diets. Following a 1-week run-in, participants in the intervention arm will receive preportioned high-fibre legume-rich entrées for two meals/ day in months 1–3 and one meal/day in months 4–6. In the control arm, entrées will replace legumes with lean protein sources (eg, chicken). Both groups will receive in-person and written guidance to include nutritionally balanced sides with energy intake to lose 1–2 pounds per week. Ethics and dissemination The National Institutes of Health fund this ongoing 5-year study through a National Cancer Institute grant (5R01CA245063) awarded to Emory University with a subaward to the University of Pittsburgh. The study protocol was approved by the Emory Institutional Review Board (IRB approval number: 00000563). Trial registration number NCT04780477.
UR - http://www.scopus.com/inward/record.url?scp=85184822937&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85184822937&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2023-081379
DO - 10.1136/bmjopen-2023-081379
M3 - Article
C2 - 38316601
AN - SCOPUS:85184822937
SN - 2044-6055
VL - 14
JO - BMJ open
JF - BMJ open
IS - 2
M1 - e081379
ER -